Abstract
RNA interference (RNAi) is a natural process by which small interfering RNA duplex directs sequencespecific post-transcriptional silencing of homologous genes by binding to its complementary mRNA and triggering its elimination. The history of RNAi has only about two decades, however, further studies have revealed that it is a potent method of gene silencing that has developed rapidly over the past few years as a result of its extensive importance in the study of genetics, molecular biology and physiology. RNAi technology has also recently yielded significant insight into dendritic cells (DCs) by helping to elucidate numerous mechanisms that regulate the development, activation and function of cells that mediate immunity. In addition, because of its ability to suppress gene expression effectively, this technique may be used to regulate the immune response for clinical purposes. As the key antigen presenting cells, DCs play a crucial part in the start of an immune response and in the enhancement and regulation of cell mediated immune reactions. The current studies indicated that targeting DCs with RNAi is a novel and effective therapeutic method for the fundamental research, and displayed great potential in clinical treatment.
Similar content being viewed by others
References
Caplen NJ (2004) Gene therapy progress and prospects downregulating gene expression the impact of RNA interference. Gene Ther 11(16):1241–1248. doi:10.1038/sj.gt.3302324
Leung RK, Whittaker PA (2005) RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol Ther 107(2):222–239. doi:10.1016/j.pharmthera.2005.03.004
Shankar P, Manjunath N, Lieberman J (2005) The prospect of silencing disease using RNA interference. JAMA 293(11):1367–1373. doi:10.1001/jama.293.11.1367
Kumar A (2008) RNA interference: a multifaceted innate antiviral defense. Retrovirology 5:17. doi:10.1186/1742-4690-5-17
He S, Zhang D, Cheng F, Gong F, Guo Y (2009) Applications of RNA interference in cancer therapeutics as a powerful tool for suppressing gene expression. Mol Biol Rep. doi:10.1007/s11033-008-9429-7
Mao CP, Lin YY, Hung CF, Wu TC (2007) Immunological research using RNA interference technology. Immunology 121(3):295–307. doi:10.1111/j.1365-2567.2007.02599.x
Vivier E, Malissen B (2005) Innate and adaptive immunity: specificities and signaling hierarchies revisited. Nat Immunol 6(1):17–21. doi:10.1038/ni1153
Hoebe K, Janssen E, Beutler B (2004) The interface between innate and adaptive immunity. Nat Immunol 5(10):971–974. doi:10.1038/ni1004-971
Seifert U, Marañón C, Shmueli A, Desoutter JF, Wesoloski L, Janek K, Henklein P, Diescher S, Andrieu M, de la Salle H, Weinschenk T, Schild H, Laderach D, Galy A, Haas G, Kloetzel PM, Reiss Y, Hosmalin A (2003) An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope. Nat Immunol 4(4):375–379. doi:10.1038/ni905
Kwon DS, Gregorio G, Bitton N, Hendrickson WA, Littman DR (2002) DC-SIGN-mediated internalization of HIV is required for trans-enhancement of T cell infection. Immunity 16(1):135–144. doi:10.1016/S1074-7613(02)00259-5
Arrighi JF, Pion M, Wiznerowicz M, Geijtenbeek TB, Garcia E, Abraham S, Leuba F, Dutoit V, Ducrey-Rundquist O, van Kooyk Y, Trono D, Piguet V (2004) Lentivirus-mediated RNA interference of DC-SIGN expression inhibits human immunodeficiency virus transmission from dendritic cells to T cells. J Virol 78(20):10848–10855. doi:10.1128/JVI.78.20.10848-10855.2004
Murdoch C, Muthana M, Lewis CE (2005) Hypoxia regulates macrophage functions in inflammation. J Immunol 175(10):6257–6263
Jantsch J, Chakravortty D, Turza N, Prechtel AT, Buchholz B, Gerlach RG, Volke M, Gläsner J, Warnecke C, Wiesener MS, Eckardt KU, Steinkasserer A, Hensel M, Willam C (2008) Hypoxia and hypoxia-inducible factor-1 alpha modulate lipopolysaccharide-induced dendritic cell activation and function. J Immunol 180(7):4697–4705
Schotte R, Nagasawa M, Weijer K, Spits H, Blom B (2004) The ETS transcription factor Spi-B is required for human plasmacytoid dendritic cell development. J Exp Med 200(11):1503–1509. doi:10.1084/jem.20041231
Choi SC, Kim KD, Kim JT, Kim JW, Yoon DY, Choe YK, Chang YS, Paik SG, Lim JS (2003) Expression and regulation of NDRG2 (N-myc downstream regulated gene 2) during the differentiation of dendritic cells. FEBS Lett 553(3):413–418. doi:10.1016/S0014-5793(03)01030-5
Choi SC, Kim KD, Kim JT, Kim JW, Lee HG, Kim JM, Jang YS, Yoon DY, Kim KI, Yang Y, Cho DH, Lim JS (2008) Expression of human NDRG2 by myeloid dendritic cells inhibits down-regulation of activated leukocyte cell adhesion molecule (ALCAM) and contributes to maintenance of T cell stimulatory activity. J Leukoc Biol 83(1):89–98. doi:10.1189/jlb.0507300
Prechtel AT, Turza NM, Theodoridis AA, Steinkasserer A (2007) CD83 knockdown in monocyte-derived dendritic cells by small interfering RNA leads to a diminished T cell stimulation. J Immunol 178(9):5454–5464
Schütz S, Chemnitz J, Spillner C, Frohme M, Hauber J, Kehlenbach RH (2006) Stimulated expression of mRNAs in activated T cells depends on a functional CRM1 nuclear export pathway. J Mol Biol 358(4):997–1009. doi:10.1016/j.jmb.2006.02.041
Prechtel AT, Chemnitz J, Schirmer S, Ehlers C, Langbein-Detsch I, Stülke J, Dabauvalle MC, Kehlenbach RH, Hauber J (2006) Expression of CD83 is regulated by HuR via a novel cis-active coding region RNA element. J Biol Chem 281(16):10912–10925. doi:10.1074/jbc.M510306200
Fries B, Heukeshoven J, Hauber I, Grüttner C, Stocking C, Kehlenbach RH, Hauber J, Chemnitz J (2007) Analysis of nucleocytoplasmic trafficking of the HuR ligand APRIL and its influence on CD83 expression. J Biol Chem 282(7):4504–4515. doi:10.1074/jbc.M608849200
Wu L, D’Amico A, Winkel KD, Suter M, Lo D, Shortman K (1998) RelB is essential for the development of myeloid-related CD8alpha- dendritic cells but not of lymphoid-related CD8alpha + dendritic cells. Immunity 9(6):839–847. doi:10.1016/S1074-7613(00)80649-4
Ouaaz F, Arron J, Zheng Y, Choi Y, Beg AA (2002) Dendritic cell development and survival require distinct NF-kappaB subunits. Immunity 16(2):257–270. doi:10.1016/S1074-7613(02)00272-8
Laderach D, Compagno D, Danos O, Vainchenker W, Galy A (2003) RNA interference shows critical requirement for NF-kappa B p50 in the production of IL-12 by human dendritic cells. J Immunol 171(4):1750–1757
Kim TW, Lee JH, He L, Boyd DA, Hardwick JM, Hung CF, Wu TC (2005) Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res 65(1):309–316
Peng S, Kim TW, Lee JH, Yang M, He L, Hung CF, Wu TC (2005) Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life. Hum Gene Ther 16(5):584–593. doi:10.1089/hum.2005.16.584
Kang TH, Lee JH, Bae HC, Noh KH, Kim JH, Song CK, Shin BC, Hung CF, Wu TC, Park JS, Kim TW (2006) Enhancement of dendritic cellbased vaccine potency by targeting antigen to endosomal/lysosomal compartments. Immunol Lett 106(2):126–134. doi:10.1016/j.imlet.2006.05.004
Evel-Kabler K, Song XT, Aldrich M, Huang XF, Chen SY (2006) SOCS1 restricts dendritic cells’ ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J Clin Invest 116(1):90–100. doi:10.1172/JCI26169
Song XT, Evel-Kabler K, Rollins L, Aldrich M, Gao F, Huang XF (2006) An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuatorsin dendritic cells. PLoS Med 3(1):e11. doi:10.1371/journal.pmed.0030011
Shen L, Evel-Kabler K, Strube R, Chen SY (2004) Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigenspecific anti-tumor immunity. Nat Biotechnol 22(12):1546–1553. doi:10.1038/nbt1035
Steinman RM, Adams JC, Cohn ZA (1975) Identification of a novel cell type in peripheral lymphoid organs of mice. IV. Identification and distribution in mouse spleen. J Exp Med 141(4):804–820
Kubo M, Hanada T, Yoshimura A (2003) Suppressors of cytokine signaling and immunity. Nat Immunol 4(12):1169–1176. doi:10.1038/ni1012
Song HF, Zhou J, Pan K, Wang QJ, Wang H, Huang LX, Li YQ, Xia JC (2008) Antitumor effects and mechanisms of a dendritic cell vaccine which silenced SOCS1 by siRNA, stimulated by OK-432 and pulsed with lysate of HepG2 cells. Ai Zheng 27(7):685–691
Maldonado-López R, Moser M (2001) Dendritic cell subsets and the regulation of Th1/Th2 responses. Semin Immunol 13(5):275–282. doi:10.1006/smim.2001.0323
Allavena P, Piemonti L, Longoni D, Bernasconi S, Stoppacciaro A, Ruco L, Mantovani A (1997) IL-10 prevents the generation of dendritic cells from CD14+ blood monocytes, promotes the differentiation to mature macrophages and stimulates endocytosis of FITC-dextran. Adv Exp Med Biol 417:323–327
De Smedt T, Van Mechelen M, De Becker G, Urbain J, Leo O, Moser M (1997) Effect of interleukin-10 on dendritic cell maturation and function. Eur J Immunol 27(5):1229–1235. doi:10.1002/eji.1830270526
Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392(6673):245–252. doi:10.1038/32588
Chhabra A, Chakraborty NG, Mukherji B (2008) Silencing of endogenous IL-10 in human dendritic cells leads to the generation of an improved CTL response against human melanoma associated antigenic epitope, MART-127–35. Clin Immunol 126(3):251–259. doi:10.1016/j.clim.2007.11.011
Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J, Cornelissen IL, Nottet HS, KewalRamani VN, Littman DR, Figdor CG, van Kooyk Y (2000) DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100(5):587–597. doi:10.1016/S0092-8674(00)80694-7
McDonald D, Wu L, Bohks SM, KewalRamani VN, Unutmaz D, Hope TJ (2003) Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science 300(5623):1295–1297. doi:10.1126/science.1084238
Steinman RM, Granelli-Piperno A, Pope M, Trumpfheller C, Ignatius R, Arrode G, Racz P, Tenner-Racz K (2003) The interaction of immunodeficiency viruses with dendritic cells. Curr Top Microbiol Immunol 276:1–30
Burns S, Cory GO, Vainchenker W, Thrasher AJ (2004) Mechanisms of WASp-mediated hematologic and immunologic disease. Blood 104(12):3454–3462. doi:10.1182/blood-2004-04-1678
Badour K, Zhang J, Siminovitch KA (2003) The Wiskott–Aldrich syndrome protein: forging the link between actin and cell activation. Immunol Rev 192:98–112. doi:10.1034/j.1600-065X.2003.00031.x
Notarangelo LD, Ochs HD (2003) Wiskott-Aldrich syndrome: a model for defective actin reorganization, cell trafficking and synapse formation. Curr Opin Immunol 15(5):585–591. doi:10.1016/S0952-7915(03)00112-2
Thrasher AJ (2002) WASp in immune-system organization and function. Nat Rev Immunol 2(9):635–646. doi:10.1038/nri884
Derry JM, Kerns JA, Weinberg KI, Ochs HD, Volpini V, Estivill X, Walker AP, Francke U (1995) WASP gene mutations in Wiskott-Aldrich syndrome and X-linked thrombocytopenia. Hum Mol Genet 4(7):1127–1135. doi:10.1093/hmg/4.7.1127
Dupuis-Girod S, Medioni J, Haddad E, Quartier P, Cavazzana-Calvo M, Le Deist F, de Saint Basile G, Delaunay J, Schwarz K, Casanova JL, Blanche S, Fischer A (2003) Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics 111(5 Pt 1):e622–e627. doi:10.1542/peds.111.5.e622
de Noronha S, Hardy S, Sinclair J, Blundell MP, Strid J, Schulz O, Zwirner J, Jones GE, Katz DR, Kinnon C, Thrasher AJ (2005) Impaired dendritic cell homing in vivo in the absence of Wiskott Aldrich syndrome protein. Blood 105(4):1590–1597. doi:10.1182/blood-2004-06-2332
Olivier A, Jeanson-Leh L, Bouma G, Compagno D, Blondeau J, Seye K, Charrier S, Burns S, Thrasher AJ, Danos O, Vainchenker W, Galy A (2006) A partial down-regulation of WASP is sufficient to inhibit podosome formation in dendritic cells. Mol Ther 13(4):729–737. doi:10.1016/j.ymthe.2005.11.003
Kawai T, Akira S (2007) TLR signaling. Semin Immunol 19(1):24–32. doi:10.1016/j.smim.2006.12.004
Kaisho T, Takeuchi O, Kawai T, Hoshino K, Akira S (2001) Endotoxin-induced maturation of MyD88-deficient dendritic cells. J Immunol 166(9):5688–5694
Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R (2001) Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2(10):947–950. doi:10.1038/ni712
Zhu C, Xu H, Zhang G, Lu C, Ji M, Wu W (2008) Myeloid differentiation factor 88-silenced bone marrow-derived dendritic cells exhibit enhanced tolerogenicity in intestinal transplantation in rats. Transpl Proc 40(5):1625–1628. doi:10.1016/j.transproceed.2008.01.070
Ryther RC, Flynt AS, Phillips JA 3rd, Patton JG (2005) siRNA therapeutics: big potential from small RNAs. Gene Ther 12(1):5–11. doi:10.1038/sj.gt.3302356
Carette JE, Overmeer RM, Schagen FH, Alemany R, Barski OA, Gerritsen WR, Van Beusechem VW (2004) Conditionally replicating adenoviruses expressing short hairpin RNAs silence the expression of a target gene in cancer cells. Cancer Res 64(8):2663–2667. doi:10.1158/0008-5472.CAN-03-3530
Song J, Pang S, Lu Y, Yokoyama KK, Zheng JY, Chiu R (2004) Gene silencing in androgen-responsive prostate cancer cells from the tissue-specific prostate-specific antigen promoter. Cancer Res 64(21):7661–7663. doi:10.1158/0008-5472.CAN-04-1751
Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm G, Molema G, Lu PY, Scaria PV, Woodle MC (2004) Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 32(19):e149. doi:10.1093/nar/gnh140
Sumimoto H, Miyagishi M, Miyoshi H, Yamagata S, Shimizu A, Taira K, Kawakami Y (2004) Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene 23(36):6031–6039. doi:10.1038/sj.onc.1207812
Sumimoto H, Yamagata S, Shimizu A, Miyoshi H, Mizuguchi H, Hayakawa T, Miyagishi M, Taira K, Kawakami Y (2005) Gene therapy for human small-cell lung carcinoma by inactivation of Skp-2 with virally mediated RNA interference. Gene Ther 12(1):95–100. doi:10.1038/sj.gt.3302391
Duxbury MS, Ito H, Benoit E, Zinner MJ, Ashley SW, Whang EE (2004) Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: a novel therapeutic strategy in pancreatic cancer. Surgery 136(2):261–269. doi:10.1016/j.surg.2004.04.029
Chen LM, Le HY, Qin RY, Kumar M, Du ZY, Xia RJ, Deng J (2005) Reversal of the phenotype by K-rasval12 silencing mediated by adenovirus-delivered siRNA in human pancreatic cancer cell line Panc-1. World J Gastroenterol 11(6):831–838
Uchida H, Tanaka T, Sasaki K, Kato K, Dehari H, Ito Y, Kobune M, Miyagishi M, Taira K, Tahara H, Hamada H (2004) Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol Ther 10(1):162–171. doi:10.1016/j.ymthe.2004.05.006
Brummelkamp TR, Bernards R, Agami R (2002) Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2(3):243–247. doi:10.1016/S1535-6108(02)00122-8
Chen J, Wall NR, Kocher K, Duclos N, Fabbro D, Neuberg D, Griffin JD, Shi Y, Gilliland DG (2004) Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin. J Clin Invest 113(12):1784–1791
Xu D, McCarty D, Fernandes A, Fisher M, Samulski RJ, Juliano RL (2005) Delivery of MDR1 small interfering RNA by self-complementary recombinant adenoassociated virus vector. Mol Ther 11(4):523–530. doi:10.1016/j.ymthe.2004.12.019
Zheng L, Liu J, Batalov S, Zhou D, Orth A, Ding S, Schultz PG (2004) An approach to genomewide screens of expressed small interfering RNAs in mammalian cells. Proc Natl Acad Sci USA 101(1):135–140. doi:10.1073/pnas.2136685100
Marques JT, Williams BR (2005) Activation of the mammalian immune system by siRNAs. Nat Biotechnol 23(11):1399–1405. doi:10.1038/nbt1161
Sioud M (2005) Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol 348(5):1079–1090. doi:10.1016/j.jmb.2005.03.013
Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A (2004) Rational siRNA design for RNA interference. Nat Biotechnol 22(3):326–330. doi:10.1038/nbt936
Kim DH, Behlke MA, Rose SD, Chang MS, Choi S, Rossi JJ (2005) Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol 23(2):222–226. doi:10.1038/nbt1051
Chiu YL, Rana TM (2002) RNAi in human cells: basic structural and functional features of small interfering RNA. Mol Cell 10(3):549–561. doi:10.1016/S1097-2765(02)00652-4
Elmen J, Thonberg H, Ljungberg K, Frieden M, Westergaard M, Xu Y, Wahren B, Liang Z, Orum H, Koch T, Wahlestedt C (2005) Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res 33(1):439–447. doi:10.1093/nar/gki193
Czauderna F, Fechtner M, Dames S, Aygun H, Klippel A, Pronk GJ, Giese K, Kaufmann J (2003) Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res 31(11):2705–2716. doi:10.1093/nar/gkg393
Allerson CR, Sioufi N, Jarres R, Prakash TP, Naik N, Berdeja A, Wanders L, Griffey RH, Swayze EE, Bhat B (2005) Fully 2′-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J Med Chem 48(4):901–904. doi:10.1021/jm049167j
Jackson AL, Burchard J, Leake D, Reynolds A, Schelter J, Guo J, Johnson JM, Lim L, Karpilow J, Nichols K, Marshall W, Khvorova A, Linsley PS (2006) Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing. RNA 12(7):1197–1205. doi:10.1261/rna.30706
Braasch DA, Jensen S, Liu Y, Kaur K, Arar K, White MA, Corey DR (2003) RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 42(26):7967–7975. doi:10.1021/bi0343774
Hall AH, Wan J, Shaughnessy EE, Ramsay Shaw B, Alexander KA (2004) RNA interference using boranophosphate siRNAs: structure–activity relationships. Nucleic Acids Res 32(20):5991–6000. doi:10.1093/nar/gkh936
Parrish S, Fleenor J, Xu S, Mello C, Fire A (2000) Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference. Mol Cell 6(5):1077–1087. doi:10.1016/S1097-2765(00)00106-4
Chiu YL, Rana TM (2003) siRNA function in RNAi: a chemical modifi cation analysis. RNA 9(9):1034–1048. doi:10.1261/rna.5103703
Lorenz C, Hadwiger P, John M, Vornlocher HP, Unverzagt C (2004) Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett 14(19):4975–4977. doi:10.1016/j.bmcl.2004.07.018
Cheng K, Ye Z, Guntaka RV, Mahato RI (2006) Enhanced hepatic uptake and bioactivity of type alpha1(I) collagen gene promoterspecific triplex-forming oligonucleotides after conjugation with cholesterol. J Pharmacol Exp Ther 317(2):797–805. doi:10.1124/jpet.105.100347
Simeoni F, Morris MC, Heitz F, Divita G (2003) Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res 31:2717–2724. doi:10.1093/nar/gkg385
Muratovska A, Eccles MR (2004) Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett 558(1–3):63–68. doi:10.1016/S0014-5793(03)01505-9
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cheng, F., He, S. RNA interference: a potent technology in studying and modulating of dendritic cells, and potential in clinical therapy. Mol Biol Rep 37, 2635–2644 (2010). https://doi.org/10.1007/s11033-009-9789-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11033-009-9789-7